Rheumatoid arthritis: non-tumor necrosis factor targets.

Martine Chabaud, Guillaume Page, Pierre Miossec, Enhancing Effect of IL-1, IL-17, and TNF-α on Macrophage Inflammatory Protein-3α Production in Rheumatoid Arthritis: Regulation by Soluble Receptors and Th2 Cytokines The Journal of Immunology. ,vol. 167, pp. 6015- 6020 ,(2001) , 10.4049/JIMMUNOL.167.10.6015

Sylvie Ferrari-Lacraz, Eric Zanelli, Manfred Neuberg, Elina Donskoy, Yon Su Kim, Xin Xiao Zheng, Wayne W. Hancock, Wlodzimierz Maslinski, Xian Chang Li, Terry B. Strom, Thomas Moll, Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. Journal of Immunology. ,vol. 173, pp. 5818- 5826 ,(2004) , 10.4049/JIMMUNOL.173.9.5818

Roy M. Fleischmann, Joy Schechtman, Ralph Bennett, Malcolm L. Handel, Gerd-Rudiger Burmester, John Tesser, Dennis Modafferi, Jennifer Poulakos, Gordon Sun, Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis & Rheumatism. ,vol. 48, pp. 927- 934 ,(2003) , 10.1002/ART.10870

J. C. W. Edwards, G. Cambridge, Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology. ,vol. 40, pp. 205- 211 ,(2001) , 10.1093/RHEUMATOLOGY/40.2.205

Barry Bresnihan, Jos� Maria Alvaro-Gracia, Mark Cobby, Michael Doherty, Zlatko Domljan, Paul Emery, George Nuki, Karel Pavelka, Rolf Rau, Blaz Rozman, Iain Watt, Bryan Williams, Roger Aitchison, Dorothy McCabe, Predrag Musikic, Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist Arthritis & Rheumatism. ,vol. 41, pp. 2196- 2204 ,(1998) , 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2

Larry W. Moreland, Rieke Alten, Filip Van Den Bosch, Thierry Appelboom, Marc Leon, Paul Emery, Stanley Cohen, Michael Luggen, William Shergy, Isaac Nuamah, Jean-Claude Becker, Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis & Rheumatism. ,vol. 46, pp. 1470- 1479 ,(2002) , 10.1002/ART.10294

Ravinder Maini, E William St Clair, Ferdinand Breedveld, Daniel Furst, Joachim Kalden, Michael Weisman, Josef Smolen, Paul Emery, Gregory Harriman, Marc Feldmann, Peter Lipsky, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial The Lancet. ,vol. 354, pp. 1932- 1939 ,(1999) , 10.1016/S0140-6736(99)05246-0

X. J. YE, B. TANG, Z. MA, A. H. KANG, L. K. MYERS, M. A. CREMER, The roles of interleukin-18 in collagen-induced arthritis in the BB rat Clinical and Experimental Immunology. ,vol. 136, pp. 440- 447 ,(2004) , 10.1111/J.1365-2249.2004.02430.X

Aris N. Economides, Laura Rocco Carpenter, John S. Rudge, Vivien Wong, Ellen M. Koehler-Stec, Christopher Hartnett, Erica A. Pyles, Xiaobing Xu, Thomas J. Daly, Michael R. Young, James P. Fandl, Frank Lee, Scott Carver, Jennifer McNay, Kevin Bailey, Swayampakula Ramakanth, Renta Hutabarat, Tammy T. Huang, Czeslaw Radziejewski, George D. Yancopoulos, Neil Stahl, Cytokine traps: multi-component, high-affinity blockers of cytokine action Nature Medicine. ,vol. 9, pp. 47- 52 ,(2003) , 10.1038/NM811

E. H. S. Choy, D. A. Isenberg, T. Garrood, S. Farrow, Y. Ioannou, H. Bird, N. Cheung, B. Williams, B. Hazleman, R. Price, K. Yoshizaki, N. Nishimoto, T. Kishimoto, G. S. Panayi, Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial Arthritis & Rheumatism. ,vol. 46, pp. 3143- 3150 ,(2002) , 10.1002/ART.10623